Distinguished in Medium-Chain Acyl-CoA Dehydrogenase Deficiency

Lawrence W. Korngut

Calgary, AB, CA 
Distinguished in Medium-Chain Acyl-CoA Dehydrogenase Deficiency
Calgary, AB, CA 
OverviewLocationsClinical Research

Overview

Lawrence Korngut practices in Calgary, Canada. Mr. Korngut is rated as a Distinguished expert by MediFind in the treatment of Medium-Chain Acyl-CoA Dehydrogenase Deficiency. His top areas of expertise are Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Medium-Chain Acyl-CoA Dehydrogenase Deficiency, Spinal Muscular Atrophy (SMA), and Thymectomy.

His clinical research consists of co-authoring 88 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Medium-Chain Acyl-CoA Dehydrogenase Deficiency.

Gender
Male

Locations

Calgary, AB, Canada
Other Locations
Vancouver, BC, Canada
Calgary, Canada
Ottawa, ON, Canada
Edmonton, AB, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Unknown
Publish Date: October 27, 2020
Intervention Type: Drug
Study Drug: AP-101
Study Phase: Phase 1
View 1 Less Clinical Trial

88 Total Publications

Best practice recommendations for the clinical care of spinal bulbar muscular atrophy.
Best practice recommendations for the clinical care of spinal bulbar muscular atrophy.
Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
Published: September 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Korngut's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile